Lymphoma Survivor Getaway Give-away!

Go into the draw to win a relaxing weekend getaway at Hangawera Lodge in Morrinsville www.hangaweralodge.co.nz.
The Leukaemia & Blood Foundation has received this lovely gift and we would like to offer survivors of leukaemia, lymphoma, myeloma or a related blood condition a chance to win a relaxing break in the country.

This $500 package includes:

  • * A weekend for 2 at Hangawera Lodge
  • * 2 nights accommodation and meals

Set in a 4 acre rural environment with beautifully established gardens, ponds and waterfalls, a 15m x 4.5m salt water swimming pool with BBQ facility, extensive pastoral views, the Hangawera Lodge promises a weekend of R&R.
To enter:

Send your details to the Leukaemia & Blood Foundation, email lbf@leukaemia.org.nz by Friday 21 August.

Please include your name and full contact details, including your postcode, and make sure your entry is clearly marked Weekend Getaway.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap